too voluminous and the time and the labour involved in the collection and compilations of the data will not be commensurate with the results likely to be achieved.

Higher Prices of Cifran, Evion, Deoml, etc.

1986. SHRI RAJNI RANJAN SAHU;

SHRI H. HANUMAN-THAPPA:

Will the PRIME MINISTER fee leased to state;

(a) whether it is a fact that price of Cifran, Clampose, Evion, Ostocal-ium, Deonil, Trehxyl etc. are substantially higer than the normal prices;

(b) what is the break up of material cost of each and what is the MAPE taken ki each as per form 2-A of price control order and what is the price of other brands of each;

(c) the basis on which Cefotaxim, Ceftazdime. Glybenclamide, Cefa-droxil and several other drugs accounting for a turn over of more than Rs. 50 lakhs are outside price control;

(d) what was their production, imports and import prices during, the last three years, year-wise and com. pany wise; and

(e) what are the prices of their for-mulations of the leading formulate, and what mark up they are having as per the break up submitted and what was the price of each before DPCO, 1987?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI EDU-ARDO FALEIRO): (a) and (b) To the extent information is available, the required details are given in the Annexure. [See Appendix CLXVI, Annexure No. 35] Except Ustocal-cium, all other formulations mentioned fall outside the price controlled category. Price of Ustocalcium is fixed/ revised from time to time in accord ance with the provisions of DPCC 1987.

(c) The issues of kiclusion/exclu sion of drugs in price control is ont of the points covered in the presen exercise of review of Drug Policy 1986, the Background Note of which has already been placed on the Tabl of both the Houses of Parliament of 12.8.92 for discussion.

(d) Production of these drugs, ex cept Glybenclamide, is not monitored To the extent available, import dat is given in the Annexure [See Appendix CLXVI, Annexure Nc 36] Production of Glybenclamide ha been 2800 kg, 3070kg and 4030kg. during 189-90. 1990-91 and 1991-92 respectively.

(e) To the extent available, infor mation is given in the Annexure [See Appendix CLXVI, Annexure No 37]

Cost of production of balk drugs

1987. SHRI RAJNI RANJAN SAHU
SHRIMATI SATYA BAHIN:

Will the PRIME MINISTER be pleased to refer to the answerto Un starred Question No. 512 given in Rajya Sabha on 26.11.92 and state:

(a) what is actual cost of productior of bulk drugs which form the basi; of price estimates by the BICP workec out without taking into consideration the inventory stocks;

(b) what justification was there with Government to increase the prices of drugs without seeing low priced stocks of intermediates consequent to devaluation of rupee;

(c) whether it is a fact that even fresh import of these intermediates

at increased, rates consequent to devaluation of rupee were not called for and the rates were also not verified; and

(d) whether it is a fact that price increases of bulk drugs were announced based on notional prices of imported inputs as well as notional consum-»ption of major inputs?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS 'AND FERTILIZERS (SHRI EDU-ARDO FALEIRO). (a) The prices of scheduled bulk drugs are fixed/revised by this Ministry on the basis of cost-cum-technical studies conducted by BICP and their detailed examination in the Ministry in accordance with the provision laid down under DPCO, 1987. BICP is an expert body of the Government in this matter. The price fixation takes into account the actual cost of production of the major part of the production of the bulk drug in the country and price is accordingly fixed so as to ensure the availability of medicines at reasonable prices.

(b) to (d) Immediately after the Govt, announced change in the exchange rate of rupee against major foreign currencies, the drug industry had strongly demanded across the board increase in prices of all bulk drugs and formulations. There were apprehensions of curtailment of production by drug units particularly of drugs having imported content leading to an emerging situation of shortages. Therefore Government decided to examine the position drug-wise and allow impact of increase in cost of imported material, since the time of the Jast price fixation, due to impact of change in Exchange rate of rupee against major foreign currencies. Increase in prices of 54 bulk drugs were calculated and given on the basis of available supporting data with the department and in consultation with the BICP. The fim-ported inputs differ from drug to drug and from manufacturer to manufacturer depending upon the stage of production and technologies etc. The vintage ot purchase and the position regarding low priced stocks will also differ from unit to unit in terms of level of stocks and the prices thereof. However the price of a bulk drug notified is one for the industry as a whole. As already explained in the earlier answer, this action was taken to ensure availability and avoid shortages.

Prices of Dexona range of formula tions

1988. SHRI H. HANUMANTHA-PPA:
SHRIMATI SATYA BAHTN:

Will the PRIME MINISTER be pleased to state:

(a) what were the approved prices of Dexona range of formulations under DPCO, 1979;

(b) on what price of the bulk drug they were based and what were the notified prices of bulk drugs;

(c) in what manner the company has been let off and what are the prices fixed by Government;

(d) whether it is a fact that the company is openly defying Govern ment fixed prices and is also using the generic as well as brand names on its packs; and

(e) what are the details thereof and what action is proposed to be taken in this regard?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI EDUAR-DO FALEIRO): (a) and (b) To the extent information is available, the notified prices of bulk drugs Dexame-